Evaxion A (EVAX) Operating Expenses (2020 - 2026)
Evaxion A's (EVAX) quarterly Operating Expenses came in at -$3.8 million in Q1 2026, up 1.27% YoY from -$3.8 million in Q1 2025, and up 5.75% on a QoQ basis from -$4.1 million in Q4 2025.
Evaxion A (EVAX) Operating Expenses (2020 - 2026) Analysis & Trends
Evaxion A (EVAX) has 7 years of Operating Expenses data on file, last reported at -$3.8 million in Q1 2026.
- Quarterly Operating Expenses rose 1.27% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.7 million (up 4.46% YoY) and the FY2025 annual result came in at -$16.8 million, up 7.27% from the prior year.
- Operating Expenses climbed to -$3.8 million in Q1 2026, from -$4.1 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $6.4 million in Q1 2022 to a low of -$6.5 million in Q4 2022.
- A 5-year average of -$2.2 million and a median of -$4.4 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses tumbled 242.25% — and 2023, when it soared 32.0%.
- Tracing EVAX's Operating Expenses over 5 years: stood at -$6.5 million in 2022, then soared by 32.0% to -$4.4 million in 2023, then climbed by 6.56% to -$4.1 million in 2024, then rose by 2.27% to -$4.1 million in 2025, then advanced by 5.75% to -$3.8 million in 2026.
- The last three Operating Expenses figures came in at -$3.8 million (Q1 2026), -$4.1 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.82 Mn |
| Dec 31, 2025 | -4.05 Mn |
| Sep 30, 2025 | -4.47 Mn |
| Jun 30, 2025 | -4.38 Mn |
| Mar 31, 2025 | -3.87 Mn |
| Dec 31, 2024 | -4.15 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Jun 30, 2024 | -4.74 Mn |
| Mar 31, 2024 | -4.45 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Sep 30, 2023 | -5.76 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | -6.30 Mn |
| Dec 31, 2022 | -6.53 Mn |
| Sep 30, 2022 | 6.08 Mn |
| Jun 30, 2022 | 6.26 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Dec 31, 2021 | 4.59 Mn |
| Sep 30, 2021 | 18.11 Mn |
| Jun 30, 2021 | 12.20 Mn |